ASH 2015 highlights in multiple myeloma by Prof. Ola Landgren

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the highlights in the field of multiple myeloma (MM), presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Prof. Landgren focuses on 3 drugs approved by the US Food and Drug Administration (FDA) in November, 2015, two monoclonal antibodies (daratumumab and elotuzumab), and the oral proteosome inhibitor ixazomib. Prof. Landgren also talks about the many combination therapies being presented at ASH 2015, involving three drugs allowing for longer progression free survival (PFS) and overall survival (OS) in MM patients. Another topic discussed by Prof. Langren is the necessity of an autologous transplant following a MM diagnosis.

Share this video